Literature DB >> 19849662

Thrombolysis for acute ischemic stroke.

M Uyttenboogaart1, J De Keyser, G J Luijckx.   

Abstract

In the last decennium, thrombolytic therapy has changed the management of acute ischemic stroke. Randomized clinical studies have demonstrated that intravenous thrombolysis with tissue plasminogen activator improves functional outcomes. Recently the time window for intravenous thrombolysis has been extended from 3 to 4.5 hours after stroke onset, which will allow more stroke patients to benefit from this treatment. Currently several studies are investigating how to improve recanalization rates of thrombolytic therapy. In this review several aspects of intravenous and intra-arterial thrombolysis are discussed.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19849662     DOI: 10.2174/156802609789869655

Source DB:  PubMed          Journal:  Curr Top Med Chem        ISSN: 1568-0266            Impact factor:   3.295


  3 in total

1.  Pathophysiology, treatment, and animal and cellular models of human ischemic stroke.

Authors:  Trent M Woodruff; John Thundyil; Sung-Chun Tang; Christopher G Sobey; Stephen M Taylor; Thiruma V Arumugam
Journal:  Mol Neurodegener       Date:  2011-01-25       Impact factor: 14.195

2.  Inhibition of cerebral ischemia/reperfusion injury-induced apoptosis: nicotiflorin and JAK2/STAT3 pathway.

Authors:  Guang-Qiang Hu; Xi Du; Yong-Jie Li; Xiao-Qing Gao; Bi-Qiong Chen; Lu Yu
Journal:  Neural Regen Res       Date:  2017-01       Impact factor: 5.135

3.  Effect of Anti-inflammatory Treatment with AMD3100 and CX3CR1 Deficiency on GABAA Receptor Subunit and Expression of Glutamate Decarboxylase Isoforms After Stroke.

Authors:  Georgios Michalettos; Helene L Walter; Ana Rita Pombo Antunes; Tadeusz Wieloch; Daniela Talhada; Karsten Ruscher
Journal:  Mol Neurobiol       Date:  2021-08-20       Impact factor: 5.590

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.